Does lower limb amputation concern all SGLT2 inhibitors?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
http://www.nature.com/articles/s41574-018-0001-9.pdf
Reference10 articles.
1. Li, D. et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab. https://doi.org/10.1016/j.diabet.2018.02.001 (2018).
2. Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
3. Khouri, C., Cracowski, J. L. & Roustit, M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes. Metab. https://doi.org/10.1111/dom.13255 (2018).
4. Inzucchi, S. E. et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41, e4–e5 (2018).
5. Monami, M. et al. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol. 54, 411–413 (2017).
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes;Diabetes, Obesity and Metabolism;2023-07-28
2. Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study;Frontiers in Pharmacology;2022-09-13
3. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2022-07-15
4. Therapie des Typ-2-Diabetes;Die Diabetologie;2022-06-13
5. Inhibiteurs des SGLT2 et risque d’amputations des membres inférieurs : plus de peur que de mal ?;Médecine des Maladies Métaboliques;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3